Biogen Pays $100M In New Isis Pharma Alliance

Law360, New York (September 9, 2013, 6:50 PM EDT) -- Biogen Idec will pay $100 million upfront to acquire exclusive rights to Isis Pharmaceuticals Inc.'s gene-altering technology, the companies said Monday, in a collaboration that seeks to develop new medications for neurological diseases.

Under the drug development partnership, Carlsbad, Calif., based Isis stands to collect as much as $220 million for every successful drug candidate developed. The six-year collaboration is designed to boost Isis's anti-sense technology, a type of therapy that alters a gene's function in order to compensate for an underlying genetic defect.

"This strategic...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.